Rubraca (Rucaparib Camsylate) Patent Expiration, LOE Window & CMS Spending

Rubraca (Rucaparib Camsylate) by Pharmaand Gmbh: FDA Orange Book core substance LOE 2031-02-10 (last listed 2035-08-17), 0 AB generics, $34.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPharmaand Gmbh
FDA Application & PathwayN209115 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-02-10
Last Listed Patent or Exclusivity Date2035-08-17
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$34.8M
2024 Medicare Part D Spend$31.5M
2024 Medicaid Spend$3.3M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel